Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.
Rath, V.L., Ammirati, M., Danley, D.E., Ekstrom, J.L., Gibbs, E.M., Hynes, T.R., Mathiowetz, A.M., McPherson, R.K., Olson, T.V., Treadway, J.L., Hoover, D.J.(2000) Chem Biol 7: 677-682
- PubMed: 10980448 
- DOI: https://doi.org/10.1016/s1074-5521(00)00004-1
- Primary Citation of Related Structures:  
1EM6, 1EXV - PubMed Abstract: 
Glycogen phosphorylases catalyze the breakdown of glycogen to glucose-1-phosphate for glycolysis. Maintaining control of blood glucose levels is critical in minimizing the debilitating effects of diabetes, making liver glycogen phosphorylase a potential therapeutic target.
Organizational Affiliation: 
Department of Exploratory Medicinal Sciences, Global Research and Development, Pfizer Inc., Groton, CT 06340, USA.